ATLANTA, Feb. 7, 2013 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has initiated coverage of Crown Marketing (OTCQB:CWNM). CWNM is revolutionizing the way people take their medication with their patented solution for Controlled Drug Delivery. In our opinion, shares of CWNM could explode as its technology becomes more widely accepted in the drug industry. CWNM's drug delivery technology maximizes the percent of the time drug plasma levels are within the therapeutic range and avoid exposure to potentially toxic (High) or sub-therapeutic (Low) levels. The real value of this technology is its ability to rescue blockbuster drugs from the dreaded Patent Cliff. In the industry, this is referred to as Life Cycle Management. CWNM's technology allows drug companies to modify the delivery, pharmacokinetics, and dosage. In addition to significantly reducing or eliminating side effects, this modification would be patentable. New patents can run for 20 years.
Controlled Drug Delivery is the length of time it takes for any medication to release and be absorbed into the body. CWNM's solution provides a more sustained release of that allows for a broad range of adaption with regards to the mode of administration, dosage form, desired release pattern, and type of compounds employed. CWNM's technology could be a cost effective solution with the capability to reduce excess overhead costs associated with chemical remanufacturing for time release medications.
The complete report is available at http://www.otcstockreview.com/CWNM_Review.pdf.
Additional information on CWNM is available on the Company's website at http://www.crowncddt.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and Crown Marketing. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about Crown Marketing, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Crown Marketing, as profiled. OTC Stock Review has been compensated five thousand dollars to perform investor relations services for Crown Marketing. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm